ClinVar Miner

Submissions for variant NM_005732.4(RAD50):c.323A>G (p.Lys108Arg) (rs542347773)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000198855 SCV000254897 uncertain significance Hereditary cancer-predisposing syndrome 2020-10-07 criteria provided, single submitter clinical testing This sequence change replaces lysine with arginine at codon 108 of the RAD50 protein (p.Lys108Arg). The lysine residue is moderately conserved and there is a small physicochemical difference between lysine and arginine. This variant is present in population databases (rs542347773, ExAC 0.06%). This variant has not been reported in the literature in individuals with RAD50-related disease. ClinVar contains an entry for this variant (Variation ID: 216628). Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: Tolerated; PolyPhen-2: Possibly Damaging; Align-GVGD: Class C0). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV000198855 SCV000663597 uncertain significance Hereditary cancer-predisposing syndrome 2019-04-03 criteria provided, single submitter clinical testing The p.K108R variant (also known as c.323A>G), located in coding exon 3 of the RAD50 gene, results from an A to G substitution at nucleotide position 323. The lysine at codon 108 is replaced by arginine, an amino acid with highly similar properties. This alteration has been reported in a cancer-free individual whose mother was diagnosed with breast cancer at age 30 from a cohort of 272 Taiwanese hereditary breast and/or ovarian cancer patients (Sung PL et al. PLoS ONE, 2017 Sep;12:e0185615). This amino acid position is highly conserved through mammals but not in all available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000780665 SCV000918124 likely benign not specified 2018-10-22 criteria provided, single submitter clinical testing Variant summary: RAD50 c.323A>G (p.Lys108Arg) results in a conservative amino acid change located in the Rad50/SbcC-type AAA domain of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 5.1e-05 in 277040 control chromosomes, exclusively within the East Asian subpopulation at a frequency of 0.00074 in the gnomAD database. The observed variant frequency within East Asian control individuals is approximately 12-fold above the estimated maximal expected allele frequency for a pathogenic variant in RAD50 causing Hereditary Breast and Ovarian Cancer phenotype (6.3e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of East Asian origin. c.323A>G has been reported in the literature in an individual with a family history of Hereditary Breast and Ovarian Cancer (Sung_2017). This report does not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and both classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.